公开(公告)号：US12102672B2

公开(公告)日：2024-10-01

申请号：US16959042

申请日：2018-12-21

申请人： INSTITUT GUSTAVE ROUSSY ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  UNIVERSITE PARIS-SACLAY ,  CENTRE HOSPITALIER UNIVERSITAIRE DE RENNES ,  UNIVERSITE DE RENNES

发明人： Laurence Zitvogel

IPC分类号： A61K39/12 ,  A61K35/76 ,  A61K45/00 ,  A61P35/00 ,  C07K14/005 ,  C07K14/74 ,  C12N5/0783 ,  C12N15/74 ,  C12Q1/02 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/543 ,  A61K39/00

CPC分类号： A61K39/12 ,  A61K35/76 ,  A61K45/00 ,  A61P35/00 ,  C07K14/005 ,  C07K14/70539 ,  C12N5/0636 ,  C12N15/746 ,  C12Q1/025 ,  C12Q1/6886 ,  G01N33/5091 ,  G01N33/54306 ,  A61K2039/5154 ,  A61K2039/523 ,  C12N2509/00 ,  C12N2795/10321 ,  C12N2795/10333 ,  C12N2795/10343 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2800/52

摘要： The present invention relates to the field of probiotic adjuvantization of anticancer treatments. In particular, the present invention concerns immunogenic sequences from a prophage present in bacteria identified as efficient adjuvants of cancer treatments. The invention provides bacterial compositions expressing immunogenic sequences from this prophage, immunogenic compositions comprising such sequences and methods using sequences from this prophage, for increasing the anticancer armamentarium.

公开(公告)号：US11123561B2

公开(公告)日：2021-09-21

申请号：US16076410

申请日：2017-02-13

申请人： UNIVERSITE DE RENNES 1 ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  CNRS (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE) ,  CHU DE RENNES (CENTRE HOSPITALIER UNIVERSITAIRE DE RENNES)

发明人： Alfredo Hernandez ,  Benoit Martin ,  Arnaud Biraben

IPC分类号： A61N1/36 ,  A61B5/00 ,  A61B5/24 ,  A61B5/04

摘要： A treatment system for stimulating the vagus nerves is described, comprising the following elements: —a detection and control unit (20); —at least one detection probe (10d, 10g) connected to the detection and control unit and intended to be applied to at least one of the two vagus nerves of a patient; —means (24) provided in the detection and control unit for detecting a phenomenon of mass discharge of action potentials in at least one vagus nerve using the detection probe or detection probes; —stimulation probes (10d, 10g) for stimulating vagus nerves, and—means (24) provided in the detection and control unit that are capable, in response to the detection of a mass discharge, of applying predefined asymmetric stimulation signals to said stimulation probes capable of causing a depolarization and/or hyperpolarization of the vagus nerves and of blocking the conduction of the action potentials at least in the efferent direction. The system is intended for preventing the risk of sudden death in the event of an epileptic seizure in epilepsy patients.

公开(公告)号：US20190091476A1

公开(公告)日：2019-03-28

申请号：US16076410

申请日：2017-02-13

申请人： UNIVERSITE DE RENNES 1 ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  CNRS (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE) ,  CHU DE RENNES (CENTRE HOSPITALIER UNIVERSITAIRE DE RENNES)

发明人： Alfredo HERNANDEZ ,  Benoit MARTIN ,  Arnaud BIRABEN

IPC分类号： A61N1/36 ,  A61B5/04 ,  A61B5/00

摘要： A treatment system for stimulating the vagus nerves is described, comprising the following elements: -a detection and control unit (20); -at least one detection probe (10d, 10g) connected to the detection and control unit and intended to be applied to at least one of the two vagus nerves of a patient; -means (24) provided in the detection and control unit for detecting a phenomenon of mass discharge of action potentials in at least one vagus nerve using the detection probe or detection probes; -stimulation probes (10d, 10g) for stimulating vagus nerves, and -means (24) provided in the detection and control unit that are capable, in response to the detection of a mass discharge, of applying predefined asymmetric stimulation signals to said stimulation probes capable of causing a depolarization and/or hyperpolarization of the vagus nerves and of blocking the conduction of the action potentials at least in the efferent direction. The system is intended for preventing the risk of sudden death in the event of an epileptic seizure in epilepsy patients.